KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares Outstanding
Ratios

Teva Pharmaceutical Industries (TEVA) Short-Term Debt repayments (2020 - 2023)

Historic Short-Term Debt repayments for Teva Pharmaceutical Industries (TEVA) over the last 4 years, with Q4 2023 value amounting to -$900.0 million.

  • Teva Pharmaceutical Industries' Short-Term Debt repayments changed N/A to -$900.0 million in Q4 2023 from the same period last year, while for Dec 2024 it was -$700.0 million, marking a year-over-year decrease of 25000.0%. This contributed to the annual value of -$700.0 million for FY2023, which is N/A changed from last year.
  • Latest data reveals that Teva Pharmaceutical Industries reported Short-Term Debt repayments of -$900.0 million as of Q4 2023.
  • In the past 5 years, Teva Pharmaceutical Industries' Short-Term Debt repayments registered a high of $500.0 million during Q4 2021, and its lowest value of -$900.0 million during Q4 2023.
  • Its 3-year average for Short-Term Debt repayments is $60.8 million, with a median of $321.5 million in 2020.
  • Examining YoY changes over the last 5 years, Teva Pharmaceutical Industries' Short-Term Debt repayments showed a top increase of 1286.68% in 2021 and a maximum decrease of 1286.68% in 2021.
  • Teva Pharmaceutical Industries' Short-Term Debt repayments (Quarter) stood at $443.0 million in 2020, then increased by 12.87% to $500.0 million in 2021, then tumbled by 280.0% to -$900.0 million in 2023.
  • Its last three reported values are -$900.0 million in Q4 2023, $200.0 million for Q3 2023, and $500.0 million during Q4 2021.